GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s stock price shot up 9.2% during mid-day trading on Friday . The company traded as high as $96.89 and last traded at $97.50. 112,807 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 609,345 shares. The stock had previously closed at $89.32.
Analyst Ratings Changes
A number of brokerages have recently issued reports on WGS. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.
Get Our Latest Report on GeneDx
GeneDx Trading Down 2.1 %
The company has a 50 day moving average of $84.69 and a two-hundred day moving average of $70.37. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The stock has a market capitalization of $2.60 billion, a PE ratio of -47.18 and a beta of 1.91.
GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. Sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.
Insider Buying and Selling
In other GeneDx news, CFO Kevin Feeley sold 1,430 shares of GeneDx stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20. Following the completion of the sale, the chief financial officer now owns 26,770 shares of the company's stock, valued at approximately $2,035,590.80. The trade was a 5.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Katherine Stueland sold 51,420 shares of GeneDx stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at approximately $162,505.60. This represents a 96.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,735 shares of company stock worth $11,719,787 in the last ninety days. 27.30% of the stock is owned by insiders.
Institutional Trading of GeneDx
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new position in shares of GeneDx in the 3rd quarter valued at about $604,000. GSA Capital Partners LLP acquired a new position in shares of GeneDx in the 3rd quarter valued at about $322,000. Royce & Associates LP acquired a new position in shares of GeneDx in the 3rd quarter valued at about $1,201,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of GeneDx in the 3rd quarter valued at about $2,547,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of GeneDx by 304.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock valued at $6,240,000 after buying an additional 110,666 shares during the period. Institutional investors and hedge funds own 61.72% of the company's stock.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
